



an Open Access Journal by MDPI

Therapeutic Radionuclides in Nuclear Medicine

Guest Editors:

Dr. Marc Pretze

1 Department of Nuclear
Medicine, University Hospital Carl
Gustav Carus, Technical
University Dresden, 01307
Dresden, Germany
2 Molecular Imaging and
Radiochemistry, Department of
Radiology and Nuclear Medicine,
Medical Faculty Mannheim,
Heidelberg University, 68167
Mannheim, Germany

Prof. Dr. Jörg Kotzerke

1 Department of Nuclear
Medicine, University Hospital Carl
Gustav Carus, Technical
University Dresden, 01307
Dresden, Germany
2 Helmholtz-Zentrum Dresden-
Rossendorf, PET Center, Institute
of Radiopharmaceutical Cancer
Research, 01328 Dresden,
Germany

Message from the Guest Editors

Sodium iodide is the first example of a theranostic radiopharmaceutical. Recently, the theranostic principle has been used with tumor receptor-specific radiopharmaceuticals containing therapeutic nuclides, such as ^{161}Tb , ^{177}Lu , ^{188}Re , ^{212}Pb , ^{225}Ac . The production mode, availability, and costs of radionuclides have a significant impact on their clinical use and is often a bottleneck for broad application. Therefore, cyclotron-produced neutrons could open a new era for producing relevant radionuclides. Combining radiotherapeutics with the body's immune system or immunotherapeutics raises hopes for immunization against cancer and could explain the success of targeted alpha therapy vs. targeted beta therapy. The value of diverse radiation qualities including options such as photodynamic therapy using Cherenkov light must be systematically investigated in vitro and in preclinical models before they can be used in clinical trials and patient care. The path from radioisotope to targeted radionuclide therapy encompasses a multitude of aspects like availability, costs, dosimetry, waste management, which will be highlighted in this issue.

Deadline for manuscript
submissions:

closed (31 January 2024)



mdpi.com/si/164230



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com